Company Overview and News
Logistics MLP MPLX LP reported Q2 earnings earlier this month that missed slightly on diluted earnings per unit despite substantially topping the revenue consensus estimate.
HOUSTON, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Targa Resources Corp. (NYSE:TRGP) ("Targa"); NextEra Energy Pipeline Holdings, LLC, an indirect, wholly-owned subsidiary of NextEra Energy Resources, LLC (NYSE: NEE) (“NextEra”); WhiteWater Midstream, LLC (“WhiteWater”), a portfolio company of Denham Capital Management and Ridgemont Energy Partners; and MPLX LP (NYSE: MPLX) (“MPLX”), announced today the execution of a letter of intent (and associated term sheets) for the joint development of the proposed Whistler Pipeline Project (“Whistler Project” or the “Project”), which will provide an outlet for increased natural gas production from the Permian Basin to growing markets along the Texas Gulf Coast.
MPLX WPXP MPC TRGP WPX NEE
Midstream outpaced the broad market and posted a fourth straight positive week. MLPs again led the way, with a 1.5% gain. The MLP Index is up 4.7% over those 4 weeks. The Alerian Midstream Energy Index (AMNA), the most inclusive midstream index, was up 0.9% and has posted a year-over-year total return of 0.1%, slightly ahead of the Alerian MLP Index.
TRP MPLX XOM SMLP EPD ENB XTO BPL HCLP CEQP ENB WPZ TRP WMB OKE MMP FANG
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET